Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | HBB | P68871 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL2523019 | 0.92 | ALDH1A1 (0.31) | ALDH1A1TSHRMEN1KMT2ATP53 | |
| Silver SCHEMBL2571872 | 0.92 | ALDH1A1 (0.31) | ALDH1A1TSHRMEN1KMT2ATP53 | |
| SCHEMBL5761679 | 0.92 | ALDH1A1 (0.31) | ALDH1A1TSHRMEN1KMT2ATP53 | |
| SCHEMBL2524418 | 0.92 | ALDH1A1 (0.31) | ALDH1A1TSHRMEN1KMT2ATP53 | |
| SCHEMBL2521151 | 0.92 | ALDH1A1 (0.31) | ALDH1A1TSHRMEN1KMT2ATP53 | |
| Potassium Ion SCHEMBL29170921 | 0.92 | ALDH1A1 (0.31) | ALDH1A1TSHRMEN1KMT2ATP53 | |
| SCHEMBL833093 | 0.83 | — | — | |
| SCHEMBL10626476 | 0.82 | ALDH1A1 (0.33) | ALDH1A1TSHRMEN1KMT2A | |
| Water SCHEMBL19915258 | 0.80 | — | — | |
| SCHEMBL7108138 | 0.79 | MEN1 (0.47) | ALDH1A1TSHRMEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12129239-B2 | Method for producing methylene disulfonate compound | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2024-10-29 | — | — | US | disclosed |
| EP-4006020-B1 | METHOD FOR PRODUCING CYCLIC DISULFONIC ACID ESTER COMPOUND | SUMITOMO SEIKA CHEMICALS (JP) | 2024-09-25 | — | — | EP | disclosed |
| CN-114144407-B | Process for producing cyclic disulfonate compound | 住友精化株式会社 | 2024-02-13 | — | — | CN | disclosed |
| US-11802119-B2 | Method for producing cyclic disulfonic acid ester compound | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2023-10-31 | — | — | US | disclosed |
| CN-116099007-A | Pamoate sustained-release composition of local anesthetic and alkaloid | 北京汇诚益健医药科技有限责任公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20220251060-A1 | METHOD FOR PRODUCING CYCLIC DISULFONIC ACID ESTER COMPOUND | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2022-08-11 | — | — | US | disclosed |
| US-20220251059-A1 | METHOD FOR PRODUCING METHYLENE DISULFONATE COMPOUND | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2022-08-11 | — | — | US | disclosed |
| EP-4006020-A1 | METHOD FOR PRODUCING CYCLIC DISULFONIC ACID ESTER COMPOUND | Sumitomo Seika Chemicals Co., Ltd. (JP) | 2022-06-01 | — | — | EP | disclosed |
| EP-4006019-A1 | METHOD FOR PRODUCING METHYLENE DISULFONATE COMPOUND | Sumitomo Seika Chemicals Co., Ltd. (JP) | 2022-06-01 | — | — | EP | disclosed |
| EP-2324027-B1 | NEW CRYSTALLINE SALT FORMS OF A 5,6,7,8-TETRAHYDRO-1,2,4- TRIAZOLO[4,3-A]PYRAZINE DERIVATIVE | MEDICHEM SA (ES) | 2016-02-24 | — | — | EP | disclosed |
| EP-2610250-B1 | METHOD FOR PRODUCING A METHYLENE DISULFONATE COMPOUND | SUMITOMO SEIKA CHEMICALS (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-9118062-B2 | Anode and method of manufacturing the same, and battery and method of manufacturing the same | SONY CORPORATION (JP) | 2015-08-25 | — | — | US | disclosed |
| US-8501966-B2 | Method for producing a methylene disulfonate compound | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| EP-2610250-A1 | METHOD FOR PRODUCING A METHYLENE DISULFONATE COMPOUND | Sumitomo Seika Chemicals Co. Ltd. (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130137881-A1 | METHOD FOR PRODUCING A METHYLENE DISULFONATE COMPOUND | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20080311472-A1 | ANODE AND METHOD OF MANUFACTURING THE SAME, AND BATTERY AND METHOD OF MANUFACTURING THE SAME | SONY CORPORATION (JP) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129239-B2 | Method for producing methylene disulfonate compound | TST, MPST, SQOR | ALDH1A1 254/4885TSHR 3410/4885MEN1 2976/4885 |
| US-20220251060-A1 | METHOD FOR PRODUCING CYCLIC DISULFONIC ACID ESTER COMPOUND | STS, TST, SCLY | ALDH1A1 260/4885TSHR 3098/4885MEN1 3251/4885 |
| US-20220251059-A1 | METHOD FOR PRODUCING METHYLENE DISULFONATE COMPOUND | TST, MPST, SQOR | ALDH1A1 254/4885TSHR 3410/4885MEN1 2976/4885 |
| US-20130137881-A1 | METHOD FOR PRODUCING A METHYLENE DISULFONATE COMPOUND | DHPS, ADH7, MPST | ALDH1A1 39/4885TSHR 3797/4885MEN1 1982/4885 |
| US-11802119-B2 | Method for producing cyclic disulfonic acid ester compound | STS, TST, SCLY | ALDH1A1 260/4885TSHR 3098/4885MEN1 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.